A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2
60
about 2.3 years
18+
Female only
7 sites in CA, LA, MI +3
What this study is about
Researchers are testing lorigerlimab, a medication, in people with advanced solid tumors. The trial will last for 852 days and involve approximately 60 participants who are female only. Participants will receive lorigerlimab by IV infusion every 21 days until cancer progresses or unacceptable side effects occur.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Lorigerlimab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
intravenous
Primary: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
Secondary: Best percent change from baseline in tumor size, Disease control rate (DCR), Frequency and severity of adverse events (AEs), serious AEs (SAEs), immune-related AEs (irAEs), and AEs leading to dose modifications or treatment discontinuation., Median duration of response (DoR) per RECIST 1.1 criteria, Median progression free survival (PFS) per RECIST 1.1 criteria, Percent change from baseline in tumor size
Oncology, Reproductive Health